Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Hubei Jumpcan Pharmaceutical Co., Ltd.

Market Cap 24.99B 3.69B 3.2B 2.95B 2.76B 5.16B 353B 5.27B 35.19B 13.62B 170B 13.84B 13.55B 592B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 14B 2.07B 1.79B 1.65B 1.55B 2.89B 198B 2.95B 19.72B 7.63B 95.37B 7.76B 7.59B 332B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
37.5%
Yield 2026 *
-
Yield 2027 * -
1 day-2.69%
1 week-4.14%
Current month-4.21%
1 month-8.21%
3 months-2.44%
6 months-5.52%
Current year+0.27%
1 week 26.02
Extreme 26.02
28.2
1 month 26.02
Extreme 26.02
29.27
Current year 24.12
Extreme 24.12
29.6
1 year 24.12
Extreme 24.12
29.6
3 years 23.85
Extreme 23.85
45.18
5 years 14.37
Extreme 14.37
45.18
10 years 14.37
Extreme 14.37
54.97
Manager TitleAgeSince
Chief Executive Officer 43 2019-12-19
Director of Finance/CFO 58 2022-09-25
Investor Relations Contact 29 2024-07-21
Director TitleAgeSince
Chairman 69 2014-03-09
Director/Board Member 64 2014-03-09
Director/Board Member 43 2014-03-09
Date Insider Type Main position Quantity % Market Cap.
11-30Buy

Director

30,000 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%-4.14%-5.21%-10.76% 3.59B
+0.82%+4.01%-11.30%-3.81% 13.31B
-1.10%-2.21%-35.37%-56.82% 4.92B
-0.22%+2.94%-9.20%-2.82% 4.74B
-1.86%-5.35%+8.38%-21.79% 3.78B
-1.61%+0.40%+2.70%-43.28% 3.76B
-0.91%+1.00%-13.63%-5.90% 3.13B
-1.50%-2.43%-13.60%-32.08% 2.25B
-6.14%-3.41%-15.13%+24.40% 1.72B
-0.89%-1.28%-18.88%-16.03% 1.68B
Average -1.61%-2.07%-11.12%-16.89% 4.29B
Weighted average by Cap. -0.85%-0.58%-11.10%-16.39%

Financials

2026 *2027 *
Net sales - -
Net income 1.72B 254M 221M 204M 191M 356M 24.36B 364M 2.43B 940M 11.74B 955M 935M 40.83B -
Net Debt - -
Logo Hubei Jumpcan Pharmaceutical Co., Ltd.
Hubei Jumpcan Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company focuses on the research and development, production and sales of drugs in the fields of pediatrics, respiratory system, digestive system and gynecology. The Company's main products include Xiao’er Chiqiao Qingre Keli, Pudilan Anti-inflammatory Oral Liquid, Huanglong Anti-cough Keli, Iron Proteinsuccinylate Oral Solution, Fuyanshu Capsules and others. The Company's products are mainly used in children's wind-heat cold with stagnation, clearing heat and detoxification, upper respiratory tract infectious diseases, acute and chronic bronchitis, gastrointestinal diseases, gynecology and other fields. The Company mainly operates its businesses in the domestic market.
Employees
4,137
Date Price Change Volume
26-06-11 26.37 ¥ -2.69% 6,895,800
26-06-10 27.10 ¥ -1.38% 4,635,421
26-06-09 27.48 ¥ -0.36% 5,031,789
26-06-08 27.58 ¥ -1.46% 5,352,497
26-06-05 27.99 ¥ +1.74% 3,954,459
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
26.37
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 600566 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!